Ye HN, Liu XY, Qin BL. Research progress of integrated traditional Chinese and Western medicine in the treatment of advanced gastric cancer. World J Gastrointest Oncol 2023; 15(1): 69-75 [PMID: 36684044 DOI: 10.4251/wjgo.v15.i1.69]
Corresponding Author of This Article
Bao-Li Qin, PhD, Chief Doctor, Department of Gastroenterology, Cancer Hospital of China Medical University; Cancer Hospital of Dalian University of Technology; Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang 110801, Liaoning Province, China. poryqin@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jan 15, 2023; 15(1): 69-75 Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.69
Research progress of integrated traditional Chinese and Western medicine in the treatment of advanced gastric cancer
Hui-Nan Ye, Xiao-Yan Liu, Bao-Li Qin
Hui-Nan Ye, Xiao-Yan Liu, Bao-Li Qin, Department of Gastroenterology, Cancer Hospital of China Medical University; Cancer Hospital of Dalian University of Technology; Liaoning Cancer Hospital & Institute, Shenyang 110801, Liaoning Province, China
Author contributions: Ye HN and Liu XY contributed equally to this work; Ye HN, Liu XY and Qin BL designed the study; Ye HN and Liu XY acquired the data; Ye HN and Liu XY analyzed and interpreted the data; Ye HN and Liu XY wrote the paper; Qin BL critically revised the manuscript for important intellectual content; all authors have read and approved the final version to be published.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bao-Li Qin, PhD, Chief Doctor, Department of Gastroenterology, Cancer Hospital of China Medical University; Cancer Hospital of Dalian University of Technology; Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang 110801, Liaoning Province, China. poryqin@126.com
Received: September 28, 2022 Peer-review started: September 28, 2022 First decision: October 21, 2022 Revised: October 28, 2022 Accepted: December 21, 2022 Article in press: December 21, 2022 Published online: January 15, 2023 Processing time: 103 Days and 21.9 Hours
Abstract
Gastric cancer (GC) is a malignant tumor originating from the gastric epithelium, and its incidence and mortality rates rank third among all malignant tumors worldwide. It is also one of the most common cancers in China and is treated predominantly by Western medicine in clinical practice. However, with the advancements in medical technology and informatics, the values of traditional Chinese medicine (TCM) in preventing and treating GC and improving prognosis have increasingly been recognized. According to TCM, clinical manifestations of GC can be divided into Yege (dysphagia), regurgitation, stomach pain, and Zhengxia (abdominal mass). Due to the unbalanced distribution of health care resources in China, most GC patients already have progressive or advanced-stage disease at the first diagnosis. As a result, most GC patients have poor physical function, and surgery or chemotherapy alone will aggravate the impairment to the immune function and seriously affect the quality of life. In contrast, TCM therapies have shown promising efficacy in the management of these patients. Here we review the role of the integrated TCM and Western medicine in treating advanced GC.
Core Tip: The incidence and mortality rates of gastric cancer (GC) rank third among all malignant tumors worldwide. In recent years, traditional Chinese medicine (TCM) has been increasingly applied in the clinical treatment of GC. The integrated TCM and the modern medicine can, to a certain extent, improve the therapeutic effects and reduce the adverse reactions caused by the modern medication in cancer treatment.
